Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH): Oseltamivir Phosphate oral suspension obtains drug registration certificate.
Novatis Biotech (688076.SH) announced that the company recently received a notice from the National Medical Products Administration (referred to as the "National Medical Products Administration")...
Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) announced that the company recently received the "Drug Registration Certificate" for the phosphoric acid oseltamivir suspension issued by the National Medical Products Administration (referred to as "NMPA") (certificate number: 2024S02238).
It is reported that the phosphoric acid oseltamivir suspension is an anti-influenza virus drug, mainly used for the treatment of influenza A and B in patients aged 2 weeks and above, as well as for the prevention of influenza A and B in individuals aged 1 year and above.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
